Impairment of quality of life in patients with antiphospholipid syndrome

Lupus

Volumn 24, Issue 11, 2015, Pages 1161-1168

  Zuily, S ^a,b,c   Rat, A C ^a,d,e   Regnault, V ^a,b,c   Kaminsky, P ^a,c   Mismetti, P ^f   Ninet, J ^g   Baillet, N ^h   Magy Bertrand, N ⁱ   Pasquali, J L ^j   Lambert, M ^k   Pasquier, E ^l   Lorcerie, B ^m   Lecompte, T ^c,n   Guillemin, F ^a,d   Wahl, D ^a,b,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM UMR S 1116 University of Lorraine   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e INSERM   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h University of Rouen   (France)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l BREST UNIVERSITY HOSPITAL   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Antiphospholipid syndrome; arterial thrombosis; MOS SF 36; quality of life; systemic lupus erythematosus

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; AGE; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; HEALTH STATUS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; THROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; THROMBOSIS;

EID: 84941206323     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315580871     Document Type: Article

References (30)

1. Miyakis S, Lockshin MD, Atsumi T,. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Cervera R, Piette JC, Font J,. Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
3. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. Epub ahead of print 24 January 2014. DOI: 10.1136/annrheumdis-2013-204838.
4. Devilliers H, Amoura Z, Besancenot JF,. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012; 51: 1906-1915.
5. Rat AC, Pouchot J, Fautrel B, Boumier P, Goupille P, Guillemin F,. Factors associated with fatigue in early arthritis: Results from a multicenter national French cohort study. Arthritis Care Res (Hoboken) 2012; 64: 1061-1069.
6. Khanna S, Pal H, Pandey RM, Handa R,. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 1536-1540.
7. Kahn SR, Hirsch A, Shrier I,. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162: 1144-1148.
8. Kahn SR, M'Lan CE, Lamping DL,. The influence of venous thromboembolism on quality of life and severity of chronic venous disease. J Thromb Haemost 2004; 2: 2146-2151.
9. Kahn SR, Elman EA, Bornais C, Blostein M, Wells PS,. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost 2005; 93: 499-502.
10. Kahn SR, Shbaklo H, Lamping DL,. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6: 1105-1112.
11. Balitsky AK, Peeva V, Su J,. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J Rheumatol 2011; 38: 1017-1019.
12. Costa SP, Lage LV, da Mota LM, de Carvalho JF,. Fibromyalgia in primary antiphospholipid (Hughes) syndrome. Lupus 2011; 20: 1182-1186.
13. Georgopoulou S, Efraimidou S, MacLennan SJ, Ibrahim F, Cox T,. Antiphospholipid (Hughes) syndrome: Description of population and health-related quality of life (HRQoL) using the SF-36. Lupus 2015; 24: 174-179.
14. Tan EM, Cohen AS, Fries JF,. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
15. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
16. Alarcón GS, McGwin G Jr, Uribe A,. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004; 51: 465-474.
17. Ware JE Jr, Kosinski M, Keller SD,. SF-36 physical and mental health summary scales: A user's manual, Boston, MA: The Health Institute, New England Medical Center, 1994.
18. Leplège A, Ecosse E, Pouchot J,. Data from general population. In: Le questionnaire MOS SF-36: manuel de l'utilisateur et guide d'interprétation des scores [The MOS SF-36 questionnaire. User manual and interpretation guide scores], Paris: Estem, 2001, pp. 67-77.
19. Ware J, Snow K, Kosinski M,. SF-36 health survey manual and interpretation guide, Boston, MA: The Health Institute, New England Medical Center, 1993.
20. Brown N, Melville M, Gray D,. Quality of life four years after acute myocardial infarction: Short form 36 scores compared with a normal population. Heart 1999; 81: 352-358.
21. Brown N, Melville M, Gray D, Young T, Skene AM, Hampton JR,. Comparison of the SF-36 health survey questionnaire with the Nottingham Health Profile in long-term survivors of a myocardial infarction. J Public Health Med 2000; 22: 167-175.
22. van Korlaar IM, Vossen CY, Rosendaal FR,. The impact of venous thrombosis on quality of life. Thromb Res 2004; 114: 11-18.
23. Cohen D, Koopmans M, Kremer Hovinga IC,. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008; 58: 2460-2469.
24. Lean ME, Han TS, Seidell JC,. Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Arch Intern Med 1999; 159: 837-843.
25. Wilson D, Parsons J, Wakefield M,. The health-related quality-of-life of never smokers, ex-smokers, and light, moderate, and heavy smokers. Prev Med 1999; 29: 139-144.
26. Laaksonen M, Rahkonen O, Martikainen P, Karvonen S, Lahelma E,. Smoking and SF-36 health functioning. Prev Med 2006; 42: 206-209.
27. Bardage C, Isacson DG,. Hypertension and health-related quality of life. An epidemiological study in Sweden. J Clin Epidemiol 2001; 54: 172-181.
28. Hyttinen L, Kekäläinen P, Vuorio AF, Sintonen H, Strandberg TE,. Health-related quality of life in elderly patients with familial hypercholesterolemia. Int J Technol Assess Health Care 2008; 24: 228-234.
29. Chambers BA, Guo SS, Siervogel R, Hall G, Chumlea WC,. Cumulative effects of cardiovascular disease risk factors on quality of life. J Nutr Health Aging 2002; 6: 179-184.
30. Giannakopoulos B, Krilis SA,. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033-1044.